- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
LLS Co-Pay Assistance Fund Hits $200 million
The Leukemia & Lymphoma Society is announcing that it has now raised more than $200 million in funding for its Co-Pay Assistance Program since its inception in 2007.
This LLS program provides patient support for prescription drug co-pays as well as health insurance premiums for blood cancer patients who meet certain income requirements.
Also eligible are patients with:
- Private insurance
- Medicare beneficiaries under Medicare Part B and/or Medicare Plan D, Medicare Supplementary Health Insurance and Medicare Advantage
Since 2007 the program has helped more than 36,000 patients.
John Walter, LLS president and CEO, said in a statement:
Receiving a diagnosis of a blood cancer can be overwhelming for a patient, and such devastating news can be compounded by an inability to afford the treatments. LLS's Co-Pay Assistance Program helps alleviate this burden for eligible patients and their families. LLS exists not only to find cures, but also to ensure access to the best available therapies for all blood cancer patients, and helping patients afford their treatments is a critical part of our mission.
To find out more
Interested patients and caregivers can learn more about this program by visiting lls.org/copay or they can call 877-LLS-COPAY.